Latest Capital Raises News

Energy Transition Minerals Ltd has successfully raised $8 million through a heavily oversubscribed Share Purchase Plan, closing early due to strong shareholder demand. The funds will support the company’s critical minerals development strategy in Europe.

Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Felix Group Holdings Ltd has announced a $1 million share purchase plan, offering eligible shareholders the chance to buy shares at $0.21 each starting 26 August 2025.

The Australian Wealth Advisors Group Ltd (AWAG) reported a $1.18 million net profit before tax in its first full year as an ASX-listed company, reversing a prior loss and growing revenue by 13%. The company expanded its funds under management and equity investments, positioning itself for further industry consolidation.

Dome Gold Mines has updated the schedule for its Share Purchase Plan, setting new dates for offer opening, closing, and share issuance through September 2025. This move aligns with ongoing development efforts at its Fiji-based mining projects.

Vital Metals Limited has had its trading suspension lifted following announcements addressing an ASX Price and Volume Query and a new capital raise, signaling renewed market activity.

Vital Metals Limited has clarified the recent spike in its share price and trading volume, attributing it to a confidential capital raise and a positive scoping study amid a broader rare earths sector rally.

360 Capital Group (ASX – TGP) reported a 15% rise in operating profit for FY25 and announced a substantial $78.8 million special distribution, reflecting strong momentum in its real estate and credit platforms.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

360 Capital Group has reported a significant profit increase for FY25 alongside a stable dividend and a substantial $0.40 per security special distribution, reflecting strong cash reserves and strategic growth in real estate credit.